Dysregulation of IL-2 and IL-8 production in circulating T lymphocytes from young cystic fibrosis patients
- PMID: 15008989
- PMCID: PMC1808972
- DOI: 10.1111/j.1365-2249.2003.02385.x
Dysregulation of IL-2 and IL-8 production in circulating T lymphocytes from young cystic fibrosis patients
Erratum in
- Clin Exp Immunol. 2004 Apr;136(1):188
Abstract
It is well documented that patients with cystic fibrosis (CF) are unable to clear persistent airway infections in spite of strong local inflammation, suggesting a dysregulation of immunity in CF. We and others have reported previously that T lymphocytes may play a prominent role in this immune imbalance. In the present work, we compared the reactivity of CD3+ T cells obtained from young CF patients in stable clinical conditions (n = 10, aged 9-16.5 years) to age-matched healthy subjects (n = 6, aged 9-13.5 years). Intracellular levels of interferon (IFN)-gamma, interleukin (IL)-2, IL-8 and IL-10 were determined by flow cytometry after whole blood culture. The data identified T lymphocyte subsets producing either low levels (M1) or high levels (M2) of cytokine under steady-state conditions. We found that the production of IFN-gamma and IL-10 by T lymphocytes was similar between young CF patients and healthy subjects. In contrast, after 4 h of activation with PMA and ionomycin, the percentage of T cells producing high levels of IL-2 (M2) was greater in CF patients (P = 0.02). Moreover, T cells from CF patients produced lower levels of IL-8, before and after activation (P = 0.007). We conclude that a systemic immune imbalance is present in young CF patients, even when clinically stable. This disorder is characterized by the capability of circulating T lymphocytes to produce low levels of IL-8 and by the emergence of more numerous T cells producing high levels of IL-2. This imbalance may contribute to immune dysregulation in CF.
Figures


Comment in
-
Lymphocytes in cystic fibrosis lung disease: a tale of two immunities.Clin Exp Immunol. 2004 Mar;135(3):358-60. doi: 10.1111/j.1365-2249.2003.02389.x. Clin Exp Immunol. 2004. PMID: 15008966 Free PMC article. No abstract available.
Similar articles
-
Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes.Clin Exp Immunol. 2000 Jun;120(3):518-25. doi: 10.1046/j.1365-2249.2000.01232.x. Clin Exp Immunol. 2000. PMID: 10844532 Free PMC article.
-
Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry.J Rheumatol. 2000 May;27(5):1128-35. J Rheumatol. 2000. PMID: 10813277
-
A whole blood method for measurement of intracellular TNF-alpha, IFN-gamma and IL-2 expression in stimulated CD3+ lymphocytes: differences between young and elderly subjects.Exp Gerontol. 2002 Jan-Mar;37(2-3):227-34. doi: 10.1016/s0531-5565(01)00188-7. Exp Gerontol. 2002. PMID: 11772508
-
Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis.J Allergy Clin Immunol. 2006 Jan;117(1):204-11. doi: 10.1016/j.jaci.2005.09.023. Epub 2005 Nov 28. J Allergy Clin Immunol. 2006. PMID: 16387607
-
Age-related differences in cell-specific cytokine production by acutely ill Malawian patients.Clin Exp Immunol. 2002 Apr;128(1):110-7. doi: 10.1046/j.1365-2249.2002.01813.x. Clin Exp Immunol. 2002. PMID: 11982598 Free PMC article.
Cited by
-
Suppression of the TGF-β pathway by a macrolide antibiotic decreases fibrotic responses by ocular fibroblasts in vitro.R Soc Open Sci. 2020 Sep 16;7(9):200441. doi: 10.1098/rsos.200441. eCollection 2020 Sep. R Soc Open Sci. 2020. PMID: 33047019 Free PMC article.
-
Azithromycin use in patients with cystic fibrosis.Eur J Clin Microbiol Infect Dis. 2015 Jun;34(6):1071-9. doi: 10.1007/s10096-015-2347-4. Epub 2015 Feb 17. Eur J Clin Microbiol Infect Dis. 2015. PMID: 25686729 Review.
-
A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients.BMC Pediatr. 2006 May 24;6:17. doi: 10.1186/1471-2431-6-17. BMC Pediatr. 2006. PMID: 16719931 Free PMC article. Clinical Trial.
-
Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes.Respir Res. 2006 Jul 30;7(1):104. doi: 10.1186/1465-9921-7-104. Respir Res. 2006. PMID: 16875506 Free PMC article.
-
Lymphocytes in cystic fibrosis lung disease: a tale of two immunities.Clin Exp Immunol. 2004 Mar;135(3):358-60. doi: 10.1111/j.1365-2249.2003.02389.x. Clin Exp Immunol. 2004. PMID: 15008966 Free PMC article. No abstract available.
References
-
- Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med. 1996;154:1229–56. - PubMed
-
- Rastogi D, Ratner AJ, Prince A. Host–bacterial interactions in the initiation of inflammation. Paediatr Respir Rev. 2001;2:245–52. - PubMed
-
- Sobonya RE, Taussig LM. Quantitative aspects of lung pathology in cystic fibrosis. Am Rev Respir Dis. 1986;134:290–5. - PubMed
-
- Muhlebach MS, Noah TL. Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am J Respir Crit Care Med. 2002;165:911–5. - PubMed
-
- Berger M. Lung inflammation early in cystic fibrosis: bugs are indicted, but the defense is guilty. Am J Respir Crit Care Med. 2002;165:857–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical